The estimated Net Worth of Karin L Walker is at least $105 Tysiąc dollars as of 24 January 2024. Ms. Walker owns over 5,000 units of Prothena plc stock worth over $104,650 and over the last 11 years she sold PRTA stock worth over $0. In addition, she makes $0 as Chief Accounting Officer i Controller at Prothena plc.
Karin has made over 30 trades of the Prothena plc stock since 2014, according to the Form 4 filled with the SEC. Most recently she exercised 5,000 units of PRTA stock worth $67,650 on 24 January 2024.
The largest trade she's ever made was exercising 23,000 units of Prothena plc stock on 20 October 2021 worth over $390,310. On average, Karin trades about 4,125 units every 73 days since 2013. As of 24 January 2024 she still owns at least 5,000 units of Prothena plc stock.
You can see the complete history of Ms. Walker stock trades at the bottom of the page.
Karin L. Walker CPA serves as Chief Accounting Officer, Controller of the Company. Prior to joining Prothena, she was Vice President, Finance and Chief Accounting Officer of Affymax, Inc. (a biopharmaceutical company), a position she held from 2012 to 2013. From 2009 to 2012, Ms. Walker was Vice President, Finance and Corporate Controller at Amyris Inc. (a biotechnology company). From 2006 to 2009, she was Vice President, Finance and Corporate Controller for CV Therapeutics, Inc. (a biopharmaceutical company). Ms. Walker also held senior financial leadership positions at Knight Ridder Digital, Accellion, Niku Corporation, Financial Engines, Inc. and NeoMagic Corporation. She earned her BS in business from the California State Polytechnic University, San Luis Obispo, and is a certified public accountant.
Karin Walker is 56, she's been the Chief Accounting Officer i Controller of Prothena plc since 2016. There are 9 older and 13 younger executives at Prothena plc. The oldest executive at Prothena Corporation plc is Christopher Henney, 78, who is the Independent Director.
Karin's mailing address filed with the SEC is C/O PROTHENA BIOSCIENCES INC, 1800 SIERRA POINT PARKWAY, BRISBANE, CA, 94005.
Over the last 12 years, insiders at Prothena plc have traded over $79,429,035 worth of Prothena plc stock and bought 2,987,732 units worth $75,619,043 . The most active insiders traders include Capital, Llc Eco R1, Co Plc Elan Corp Plc Elan S... oraz Helen Susan Kim. On average, Prothena plc executives and independent directors trade stock every 21 days with the average trade being worth of $946,769. The most recent stock trade was executed by Karin L Walker on 24 January 2024, trading 5,000 units of PRTA stock currently worth $67,650.
prothena corporation plc (nasdaq: prta) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. the company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications, including al amyloidosis (neod001), parkinson’s disease and other related synucleinopathies (prx002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (prx003). our lead program, neod001, is in a global phase 3 registration clinical trial – the vital amyloidosis study. there is also an on-going phase 1/2 trial. prx002 is in a phase 1 multiple ascending dose clinical trial, and prx003 is in a phase 1 single ascending dose clinical trial. prothena’s elite team has a recognized track record both f
Prothena plc executives and other stock owners filed with the SEC include: